SEPN: Septerna, Inc. Company Value to Net Income
Septerna Inc lacks current sales, as its success depends on scientific grants. Management is focusing on GPCR receptors to combat metabolic pathologies. However, the scaling potential through patents promises colossal margins, which is confirmed by the company's base P/E on GURU.Markets, where -96.80 is the current value of the indicator, helping to avoid overpaying for the asset in a timely manner.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_SEPN_-_Septerna-Inc_-_PE-Multiple "SEPN: Septerna Inc Business Payback Period 05/17/2025 - 11/10/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Septerna Corp (SEPN)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
- earnings and market multiples details:
SEPN - Net Profit|Expected Net Profit Septerna Inc|SEPN - Price to Earnings Ratio|Price to Expected Earnings Ratio Septerna, Inc.|SEPN - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Septerna Inc|SEPN - Operating profit EBITDA|Net earnings per one share for the last twelve months Septerna|SEPN - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months septerna.com|SEPN - Earnings per share growth in current year|Projected earnings per share growth rate for next year Septerna Inc
Comprehensive company analysis:septerna.com SEPN
The innovative Native Complex platform enables Septerna Inc (SEPN) to develop oral drugs for previously inaccessible GPCR receptors, delivering a technological breakthrough in endocrinology. The company's P/E valuation profile reflects the market value of one dollar of net income, allowing for a determination of the asset's premium and an assessment of the stock's resilience to changes in government subsidies and the tax regime.
Key competitors
P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|ABCL - Price to Earnings Ratio|Business Payback Period Tourmaline TRML|PGEN: P/E Multiple|Market Cap to Earnings pharming.com (PHAR)|Price to Earnings Ratio Nektar Therapeutics Inc.|Upstream Bio, Inc. - Market Cap to Net Income|Price to Earnings Ratio ZBIO (Zenas Biopharma, Inc.)|Market Price to Net Income Ratio IMNM|P/E Multiple GOSS (Gossamer Bio, Inc.)|kalvista.com (KALV) - Market Cap to Earnings|PVLA - Price to Earnings Ratio|Company Value to Net Income SVRA (Savara Inc)|Rigel Pharmaceuticals Inc (RIGL) - Price to Earnings Ratio|Price to Earnings Multiple ANAB|ATXS (Astria Therapeutics) - P/E Multiple|P/E Multiple engene.com|Price to Earnings Ratio RAPT (RAPT Therapeutics)|JBIO (aerovatetx.com) - Company Value to Net Income|P/E Multiple ACRS (Aclaris)|Business Payback Period Kyverna Therapeutics, Inc (KYTX)|TLSA - Price to Earnings Ratio|CABA (cabalettabio.com) - Price to Earnings Multiple|VTYX: P/E Multiple|Price to Earnings Ratio Theratechnologies, Inc.|Price to Earnings Ratio Avalo Therapeutics Inc.|Eledon Pharmaceuticals, Inc (ELDN) - Business Payback Period|P/E Multiple AGEN|CLYM - Market Cap to Earnings|Price to Earnings Ratio Zura Bio ZURA|ATYR (aTyr Pharma Inc) - Market Cap to Net Income|ADAG - Price to Earnings Ratio|IMA (ImageneBio Inc) - Price to Earnings Multiple|shattucklabs.com (STTK) - Price to Earnings Ratio|Market Cap to Net Income EQ (Equillium)|CNTB (Connect Biopharma Holdings) - P/E Multiple|IMUX: Company Value to Net Income|P/E Multiple ATRA|P/E Multiple inflarx.de (IFRX)|Price to Earnings Ratio X4 Pharmaceuticals XFOR|Company Value to Net Income ACET|CELU - Price to Earnings Ratio|INmune Bio Inc (INMB) - Price to Earnings Ratio|BRNS: P/E Multiple|Kezar Life Sciences Inc (KZR) - P/E Multiple|Price to Earnings Ratio SABS|AKTX: Company Value to Net Income|P/E Multiple ENLV|Business Payback Period q32bio.com|Price to Earnings Ratio GeoVax Labs Inc GOVX|EDSA - Price to Earnings Ratio|IBIO - Price to Earnings Ratio|Carisma Therapeutics (CARM) - Price to Earnings Ratio|XTLB (XTL Biopharmaceuticals Ltd.) - Price to Earnings Ratio|Bolt Biotherapeutics, Inc. (BOLT) - P/E Multiple|Price to Earnings Ratio HCW Biologics, Inc.|Price to Earnings Multiple APVO (Aptevo)|P/E Multiple AIM|ADTX - Market Cap to Earnings|Price to Earnings Ratio GRI Bio GRI|Business Payback Period XORTX Therapeutics Inc (XRTX)|ReShape Lifesciences - P/E Multiple|Market Cap to Earnings Revelation Biosciences Corp|Indaptus Therapeutics (INDP) - Price to Earnings Ratio|Market Cap to Net Income SCNI (scinai.com)|Price to Earnings Ratio CALI|AFMD (Affimed Therapeutics) - Market Price to Net Income Ratio|P/E Multiple ALLK|HOOK - Market Cap to Earnings|Price to Earnings Ratio IGM Biosciences IGMS|Company Value to Net Income ITOS|OCEA - Price to Earnings Ratio|TCBP (TC BioPharm (Holdings) Plc) - Price to Earnings Multiple|THRD: P/E Multiple
